Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study

References

• Akhtar, M. W., Raingo, J., Nelson, E. D., Montgomery, R. L., Olson, E. N., Kavalali, E. T., & Monteggia, L. M. (2009). Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. Journal of Neuroscience, 29 (25), 8288–8297. doi:10.1523/JNEUROSCI.0097-09.2009
   PubMed Web of Science ®Google Scholar
• Arora, R., Issar, U., & Kakkar, R. (2018). In silico study of the active site of Helicobacter pylori urease and its inhibition by hydroxamic acids. Journal of Molecular Graphics and Modelling, 83, 64–73. doi:10.1016/j.jmgm.2018.04.018
   PubMed Web of Science ®Google Scholar
• Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008). A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 22 (5), 1026–1034. doi:10.1038/leu.2008.9
   PubMed Web of Science ®Google Scholar
• Bergman, J. A., Woan, K., Perez-Villarroel, P., Villagra, A., Sotomayor, E. M., & Kozikowski, A. P. (2012). Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. Journal of Medicinal Chemistry, 55 (22), 9891–9899. doi:10.1021/jm301098e
   PubMed Web of Science ®Google Scholar
• Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., … Gangloff, A. R. (2010). Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl) benzamides. Bioorganic & Medicinal Chemistry Letters, 20 (10), 3142–3145. doi:10.1016/j.bmcl.2010.03.091
   PubMed Web of Science ®Google Scholar
• Bürli, R. W., Luckhurst, C. A., Aziz, O., Matthews, K. L., Yates, D., Lyons, K. A., … Dominguez, C. (2013). Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington’s disease. Journal of Medicinal Chemistry, 56 (24), 9934–9954. doi:10.1021/jm4011884
   PubMed Web of Science ®Google Scholar
• Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010). Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. Journal of the American Chemical Society, 132 (31), 10842–10846. doi:10.1021/ja102758v
   PubMed Web of Science ®Google Scholar
• Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019). HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene, 38 (39), 6599–6614. doi:10.1038/s41388-019-0897-0
   PubMed Web of Science ®Google Scholar
• Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., … Jung, M. (2016). Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. Future Medicinal Chemistry, 8 (13), 1609–1634. doi:10.4155/fmc-2016-0117
   PubMed Web of Science ®Google Scholar
• Cook, C., Carlomagno, Y., Gendron, T. F., Dunmore, J., Scheffel, K., Stetler, C., … Petrucelli, L. (2014). Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Human molecular Genetics, 23 (1), 104–116. doi:10.1093/hmg/ddt402
   PubMed Web of Science ®Google Scholar
• de Freitas, R. F., & Schapira, M. (2017). A systematic analysis of atomic protein–ligand interactions in the PDB. MedChemComm, 8, 1970–1981. doi:10.1039/C7MD00381A
   PubMed Web of Science ®Google Scholar
• Dovey, O. M., Foster, C. T., Conte, N., Edwards, S. A., Edwards, J. M., Singh, R., … Cowley, S. M. (2013). Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood, 121 (8), 1335–1344. doi:10.1182/blood-2012-07-441949
   PubMed Web of Science ®Google Scholar
• Duvic, M., & Vu, J. (2007). Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs, 16 (7), 1111–1120. doi:10.1517/13543784.16.7.1111
   PubMed Web of Science ®Google Scholar
• Falkenberg, K. J., & Johnstone, R. W. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature Reviews Drug Discovery, 13 (9), 673–691. doi:10.1038/nrd4360
   PubMed Web of Science ®Google Scholar
• Feldblum, E. S., & Arkin, I. T. (2014). Strength of a bifurcated H bond. Proceedings of the National Academy of Sciences of the United States of America, 111 (11), 4085–4090. doi:10.1073/pnas.1319827111
   PubMed Web of Science ®Google Scholar
• Fenichel, M. P. (2015). FDA approves new agent for multiple myeloma. Jnci Journal of the National Cancer Institute, 107 (6), djv165–djv165. doi:10.1093/jnci/djv165
   PubMedGoogle Scholar
• Fischle, W., Dequiedt, F., Fillion, M., Hendzel, M. J., Voelter, W., & Verdin, E. (2001). Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. Journal of Biological Chemistry, 276 (38), 35826–35835. doi:10.1074/jbc.M104935200
   PubMed Web of Science ®Google Scholar
• Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002). Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Molecular Cell, 9 (1), 45–57. doi:10.1016/S1097-2765(01)00429-4
   PubMed Web of Science ®Google Scholar
• Fukada, M., Hanai, A., Nakayama, A., Suzuki, T., Miyata, N., Rodriguiz, R. M., … Kawaguchi, Y. (2012). Loss of deacetylation activity of Hdac6 affects emotional behavior in mice. PloS One, 7 (2), e30924. doi:10.1371/journal.pone.0030924
   PubMed Web of Science ®Google Scholar
• Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., … Tsai, L.-H. (2012). An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature, 483 (7388), 222–226. doi:10.1038/nature10849
   PubMed Web of Science ®Google Scholar
• Grant, C., Rahman, F., Piekarz, R., Peer, C., Frye, R., Robey, R. W., … Bates, S. E. (2010). Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy, 10 (7), 997–1008. doi:10.1586/era.10.88
   PubMed Web of Science ®Google Scholar
• Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., … Tsai, L.-H. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 459 (7243), 55–60. doi:10.1038/nature07925
   PubMed Web of Science ®Google Scholar
• Hai, Y., & Christianson, D. W. (2016). Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nature Chemical Biology, 12 (9), 741–750. doi:10.1038/nchembio.2134
   PubMed Web of Science ®Google Scholar
• Hai, Y., Shinsky, S. A., Porter, N. J., & Christianson, D. W. (2017). Histone deacetylase 10 structure and molecular function as a polyamine deacetylase. Nature Communications, 8 (1), 15368–15376. doi:10.1038/ncomms15368
   PubMed Web of Science ®Google Scholar
• Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. The Prostate, 59 (2), 177–189. doi:10.1002/pros.20022
   PubMed Web of Science ®Google Scholar
• Heideman, M. R., Wilting, R. H., Yanover, E., Velds, A., de Jong, J., Kerkhoven, R. M., … Dannenberg, J.-H. (2013). Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood, 121 (11), 2038–2050. doi:10.1182/blood-2012-08-450916
   PubMed Web of Science ®Google Scholar
• Huang, P., Almeciga-Pinto, I., Jarpe, M., van Duzer, J. H., Mazitschek, R., Yang, M., … Quayle, S. N. (2017). Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget, 8, 2694–2707. doi:10.18632/oncotarget.13738
   PubMedGoogle Scholar
• Huang, W.-J., Wang, Y.-C., Chao, S.-W., Yang, C.-Y., Chen, L.-C., Lin, M.-H., … Chang, C.-I. (2012). Synthesis and biological evaluation of ortho‐aryl N‐hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform‐selective inhibitors. ChemMedChem, 7 (10), 1815–1824. doi:10.1002/cmdc.201200300
   PubMed Web of Science ®Google Scholar
• Kashyap, K., & Kakkar, R. (2019). An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies. Journal of Biomolecular Structure and Dynamics, 38, 48–65. doi:10.1080/07391102.2019.1567388
   PubMed Web of Science ®Google Scholar
• Kellenberger, E., Rodrigo, J., Muller, P., & Rognan, D. (2004). Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins: Structure, Function, and Bioinformatics, 57 (2), 225–242. doi:10.1002/prot.20149
   PubMed Web of Science ®Google Scholar
• Kim, M.-S., Akhtar, M. W., Adachi, M., Mahgoub, M., Bassel-Duby, R., Kavalali, E. T., … Monteggia, L. M. (2012). An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. Journal of Neuroscience, 32 (32), 10879–10886. doi:10.1523/JNEUROSCI.2089-12.2012
   PubMed Web of Science ®Google Scholar
• Kontoyianni, M., McClellan, L. M., & Sokol, G. S. (2004). Evaluation of docking performance: Comparative data on docking algorithms. Journal of Medicinal Chemistry, 47 (3), 558–565. doi:10.1021/jm0302997
   PubMed Web of Science ®Google Scholar
• KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007). Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorganic & Medicinal Chemistry Letters, 17 (10), 2874–2878. doi:10.1016/j.bmcl.2007.02.064
   PubMed Web of Science ®Google Scholar
• Kumari, T., Issar, U., & Kakkar, R. (2015). Docking modes of BB-3497 into the PDF active site – A comparison of the pure MM and QM/MM based docking strategies. Current Computer Aided-Drug Design, 10 (4), 315–326.
   Web of Science ®Google Scholar
• Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., … Steiner, P. (2013). Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. Journal of Biological Chemistry, 288 (37), 26926–26943. doi:10.1074/jbc.M113.490706
   PubMed Web of Science ®Google Scholar
• Luckhurst, C. A., Breccia, P., Stott, A. J., Aziz, O., Birch, H. L., Bürli, R. W., … Dominguez, C. (2016). Potent, selective, and CNS-penetrant tetrasubstituted cyclopropane class IIa histone deacetylase (HDAC) inhibitors. ACS Medicinal Chemistry Letters, 7 (1), 34–39. doi:10.1021/acsmedchemlett.5b00302
   PubMed Web of Science ®Google Scholar
• Majdzadeh, N., Wang, L., Morrison, B. E., Bassel‐Duby, R., Olson, E. N., & D'Mello, S. R. (2008). HDAC4 inhibits cell‐cycle progression and protects neurons from cell death. Developmental Neurobiology, 68 (8), 1076–1092. doi:10.1002/dneu.20637
   PubMed Web of Science ®Google Scholar
• Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015). Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules, 20 (3), 3898–3941. doi:10.3390/molecules20033898
   PubMed Web of Science ®Google Scholar
• Musah, R. A., Jensen, G. M., Rosenfeld, R. J., McRee, D. E., Goodin, D. B., & Bunte, S. W. (1997). Variation in strength of an unconventional C − H to O hydrogen bond in an engineered protein cavity. Journal of the American Chemical Society, 119 (38), 9083–9084. doi:10.1021/ja9716766
   Web of Science ®Google Scholar
• Pierce, A. C., Jacobs, M., & Stuver-Moody, C. (2008). Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. Journal of Medicinal Chemistry, 51 (6), 1972–1975. doi:10.1021/jm701248t
   PubMed Web of Science ®Google Scholar
• Pierce, A. C., Sandretto, K. L., Bemis, G. W. (2002). Kinase inhibitors and the case for CH…O hydrogen bonds in protein–ligand binding. Proteins: Structure, Function, and Genetics, 49 (4), 567–576. doi:10.1002/prot.10259
   PubMed Web of Science ®Google Scholar
• Poole, R. M. (2014). Belinostat: First global approval. Drugs, 74 (13), 1543–1554. doi:10.1007/s40265-014-0275-8
   PubMed Web of Science ®Google Scholar
• Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017). Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors. Proceedings of the National Academy of Sciences, 114 (51), 13459–13464. doi:10.1073/pnas.1718823114
   PubMed Web of Science ®Google Scholar
• Porter, N. J., Osko, J. D., Diedrich, D., Kurz, T., Hooker, J. M., Hansen, F. K., & Christianson, D. W. (2018). Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity. Journal of Medicinal Chemistry, 61 (17), 8054–8060. doi:10.1021/acs.jmedchem.8b01013
   PubMed Web of Science ®Google Scholar
• Rasheed, W., Bishton, M., Johnstone, R. W., & Prince, H. M. (2008). Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Review of Anticancer Therapy, 8 (3), 413–432. doi:10.1586/14737140.8.3.413
   PubMed Web of Science ®Google Scholar
• Ravindranathan, K. P., Mandiyan, V., Ekkati, A. R., Bae, J. H., Schlessinger, J., & Jorgensen, W. L. (2010). Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. Journal of Medicinal Chemistry, 53 (4), 1662–1672. doi:10.1021/jm901386e
   PubMed Web of Science ®Google Scholar
• Riccardi, L., Genna, V., & De Vivo, M. (2018). Metal–ligand interactions in drug design. Nature Reviews Chemistry, 2 (7), 100–112. doi:10.1038/s41570-018-0018-6
   Web of Science ®Google Scholar
• Roche, J., & Bertrand, P. (2016). Inside HDACs with more selective HDAC inhibitors. European Journal of Medicinal Chemistry, 121, 451–483. doi:10.1016/j.ejmech.2016.05.047
   PubMed Web of Science ®Google Scholar
• Santoro, F., Botrugno, O. A., Dal Zuffo, R., Pallavicini, I., Matthews, G. M., Cluse, L., … Minucci, S. (2013). A dual role for Hdac1: Oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood, 121 (17), 3459–3468. doi:10.1182/blood-2012-10-461988
   PubMed Web of Science ®Google Scholar
• Selenica, M. L., Benner, L., Housley, S. B., Manchec, B., Lee, D. C., Nash, K. R., … Morgan, D. (2014). Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's research & Therapy, 6, 12. doi:10.1186/alzrt241
   PubMed Web of Science ®Google Scholar
• Sengupta, N., & Seto, E. (2004). Regulation of histone deacetylase activities. Journal of Cellular Biochemistry, 93 (1), 57–67. doi:10.1002/jcb.20179
   PubMed Web of Science ®Google Scholar
• Shen, J., Tan, C., Zhang, Y., Li, X., Li, W., Huang, J., … Tang, Y. (2010). Discovery of potent ligands for estrogen receptor β by structure-based virtual screening. Journal of Medicinal Chemistry, 53 (14), 5361–5365. doi:10.1021/jm100369g
   PubMed Web of Science ®Google Scholar
• Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S. W. (2010). Nonhistone protein acetylation as cancer therapy targets. Expert Review of Anticancer Therapy, 10 (6), 935–954. doi:10.1586/era.10.62
   PubMed Web of Science ®Google Scholar
• Suzuki, T., Muto, N., Bando, M., Itoh, Y., Masaki, A., Ri, M., … Miyata, N. (2014). Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8‐selective inhibitors. ChemMedChem, 9 (3), 657–664. doi:10.1002/cmdc.201300414
   PubMed Web of Science ®Google Scholar
• Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., … Miyata, N. (2012). Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. Journal of Medicinal Chemistry, 55 (22), 9562–9575. doi:10.1021/jm300837y
   PubMed Web of Science ®Google Scholar
• Tabackman, A. A., Frankson, R., Marsan, E. S., Perry, K., & Cole, K. E. (2016). Structure of ‘linkerless’ hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket. Journal of Structural Biology, 195 (3), 373–378. doi:10.1016/j.jsb.2016.06.023
   PubMed Web of Science ®Google Scholar
• Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., … Di Marco, S. (2004). Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proceedings of the National Academy of Sciences, 101 (42), 15064–15069. doi:10.1073/pnas.0404603101
   PubMed Web of Science ®Google Scholar
• Wagner, F. F., Weïwer, M., Steinbacher, S., Schomburg, A., Reinemer, P., Gale, J. P., … Holson, E. B. (2016). Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors. Bioorganic & Medicinal Chemistry, 24 (18), 4008–4015. doi:10.1016/j.bmc.2016.06.040
   PubMed Web of Science ®Google Scholar
• Whitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., … Stams, T. (2011). Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorganic & Medicinal Chemistry, 19 (15), 4626–4634. doi:10.1016/j.bmc.2011.06.030
   PubMed Web of Science ®Google Scholar
• Xie, R., Li, Y., Tang, P., & Yuan, Q. (2018). Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. European Journal of Medicinal Chemistry, 143, 320–333.
   PubMed Web of Science ®Google Scholar
• Zhao, C., Zang, J., Ding, Q., Inks, E. S., Xu, W., Chou, C. J., & Zhang, Y. (2018). Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. European Journal of Medicinal Chemistry, 150, 282–291.
   PubMed Web of Science ®Google Scholar
• Zhou, Z., Felts, A. K., Friesner, R. A., & Levy, R. M. (2007). Comparative performance of several flexible docking programs and scoring functions: Enrichment studies for a diverse set of pharmaceutically relevant targets. Journal of Chemical Information and Modeling, 47 (4), 1599–1608. doi:10.1021/ci7000346
   PubMed Web of Science ®Google Scholar
• Zimmermann, S., Kiefer, F., Prudenziati, M., Spiller, C., Hansen, J., Floss, T., … Göttlicher, M. (2007). Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Research, 67(19), 9047–9054. doi:10.1158/0008-5472.CAN-07-0312
   PubMed Web of Science ®Google Scholar